Northwest Biotherapeutics Files 2024 10-K
Ticker: NWBO · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1072379
| Field | Detail |
|---|---|
| Company | Northwest Biotherapeutics Inc (NWBO) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, warrants
TL;DR
NWBO 2024 10-K filed. Warrant liability $7.32M. Investors watch valuation inputs.
AI Summary
Northwest Biotherapeutics Inc. reported its 2024 fiscal year results, ending December 31, 2024. The company's filing indicates significant financial activities, including warrant liabilities valued at $7.32 million, with associated risk-free interest rates, price volatility, and expected term inputs for fair value calculations as of December 31, 2024. The company is based in Bethesda, MD.
Why It Matters
This filing provides a year-end financial snapshot for Northwest Biotherapeutics, crucial for investors assessing the company's financial health and valuation, particularly concerning its warrant liabilities.
Risk Assessment
Risk Level: medium — The company's financial disclosures, particularly regarding warrant liabilities and their valuation inputs, suggest a level of financial complexity and potential volatility.
Key Numbers
- $7.32M — Warrant Liability (Fair value of outstanding warrants as of December 31, 2024.)
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K filing.)
Key Players & Entities
- NORTHWEST BIOTHERAPEUTICS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- $7.32 million (dollar_amount) — Warrant Liability Value
- BETHESDA, MD (location) — Company Headquarters
FAQ
What was the total revenue for Northwest Biotherapeutics in the fiscal year ending December 31, 2024?
The provided snippet does not contain specific total revenue figures for the fiscal year ending December 31, 2024.
What is the nature of the 'Warrant Liability' mentioned and how is it valued?
The filing mentions a 'Warrant Liability' valued at $7.32 million as of December 31, 2024, with valuation inputs including risk-free interest rate, price volatility, and expected term.
What are the key inputs used for the fair value measurement of the warrant liability?
The key inputs for the fair value measurement of the warrant liability include the risk-free interest rate, price volatility, and expected term, categorized under 'FairValueInputsLevel3Member'.
Where is Northwest Biotherapeutics Inc. headquartered?
Northwest Biotherapeutics Inc. is headquartered in Bethesda, MD, with its business and mailing addresses listed at 4800 Montgomery Lane, Suite 800.
What is the SEC file number for this 10-K filing?
The SEC file number for this 10-K filing is 001-35737.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding NORTHWEST BIOTHERAPEUTICS INC (NWBO).